Relation between Blood Pressure Management and Renal Effects of Sodium-Glucose Cotransporter 2 Inhibitors in Diabetic Patients with Chronic Kidney Disease
Table 1
Differences among the study groups based on blood pressure at initiation of treatment and MAP at the time of survey.
BP (mmHg) at initiation of SGLT2i treatment
Well-controlled group ()
Poorly controlled group ()
value
Age (years)
<0.001
Sex, males : females
210 : 117
273 : 140
n.s.
BW (kg)
<0.001
BMI (kg/m2)
<0.001
SBP/DBP at office (mmHg)
<0.001/<0.001
MAP at office (mmHg)
<0.001
HbA1c (mmol/mol) (%)
()
()
n.s.
eGFR (ml/min/1.7 m2)
0.002
CCR (ml/min)
<0.001
ACR (mg/gCr)
38.1 (13.3, 103.6)
58.5 (24.0, 185.9)
<0.001
Logarithmic value of ACR
<0.001
,
125/167/35
114/224/75
<0.001
Duration of treatment (months)
15 (11, 22)
12 (10, 24)
n.s.
MAP (mmHg) at the time of the survey
<102 ()
≥102 ()
value
Age (years)
<0.001
Sex, males : females
337 : 200
146 : 57
0.02
BW (kg)
<0.001
BMI (kg/m2)
<0.001
SBP/DBP at office (mmHg)
<0.001/<0.001
MAP at office (mmHg)
<0.001
HbA1c (mmol/mol) (%)
()
()
n.s.
eGFR (ml/min/1.7 m2)
0.018
CCR (ml/min)
<0.001
ACR (mg/gCr)
42.6 (16.2, 140.0)
58.5 (26.1, 164.9)
0.023
Logarithmic value of ACR
0.027
,
185/275/77
54/116/33
n.s.
Duration of treatment (months)
15 (11, 23)
12 (8, 24)
n.s.
,¶, compared with the other group (in two-group comparisons); §, compared with the <125/75 group; and †, compared with the ≥130/80 to <135/85 group. Abbreviations: ACR: urinary albumin-creatinine ratio; BMI: body mass index; BW: body weight; SBP: systolic blood pressure; DBP: diastolic blood pressure; CCR: creatinine clearance, calculated by the Cockcroft-Gault formula; eGFR: estimated glomerular filtration rate; HbA1c: hemoglobin A1c; MAP: mean arterial pressure; n.s.: not significant; SGLT2i: sodium-glucose cotransporter 2 inhibitors.
